Keep up-to-date with PrECOG by visiting our news page regularly.
Clinical Cancer Research has published a report detailing the safety and efficacy of pelareorep combined with paclitaxel chemotherapy, with or without the checkpoint inhibitor avelumab, for patients whose disease progressed after first-line treatment
Trial PrE0405 met its primary endpoint. Venetoclax combined with bendamustine+rituximab as the first therapy for MCL in patients over age 60 led to a complete response rate of 85%. The American Society of Hematology 2023 annual meeting featured the data.
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition, occurring in San Diego, California and virtually December 9 – 12, 2023.
Researchers with PrECOG, LLC, are presenting updates and new data at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June.
In-depth molecular analyses of responding tumors provide insights into patient selection methods for this novel chemo-immunotherapy regimen, which is currently being evaluated in the DREAM3R phase 3 trial, open to patients in the US, Australia, and New Zealand